Arvinas (ARVN) Q2 2026 Earnings Call Transcript

Arvinas reported strong second-quarter 2026 financial results and outlined updated program timelines during its Aug. 4, 2026 earnings call. Total revenue reached $249.7 million, driven by $62.5 million from the Rigel license and a $50 million milestone payment from Pfizer tied to the first-ever FDA approval of a PROTAC degrader, VEPPANU. Net income was $169.4 million versus a net loss of $61.2 million a year earlier, and basic EPS rose to $2.61. Management said it ended the quarter with $567.9 million in cash and marketable securities, projecting runway into the second half of 2028. Research and development expenses were $52.6 million, and the company provided milestones including ARV-6723 enrollment in 3Q 2026 and ARV-102 clinical start in 2027.